Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance. - Barron's
Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance. Barron's
Novo Nordisk Could Win the Oral GLP-1 Race Against Lilly. Why It Just Raised Guidance. Barron's
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.